Adicet Bio, Inc. (ACET)
| Market Cap | 97.52M +40.8% |
| Revenue (ttm) | n/a |
| Net Income | -98.97M |
| EPS | -10.52 |
| Shares Out | 10.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 111,229 |
| Open | 9.22 |
| Previous Close | 9.01 |
| Day's Range | 8.76 - 9.25 |
| 52-Week Range | 6.01 - 17.44 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 33.17 (+266.12%) |
| Earnings Date | Aug 5, 2026 |
About ACET
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ACET stock is "Strong Buy." The 12-month stock price target is $33.17, which is an increase of 266.12% from the latest price.
News
Adicet Bio announces FDA clearance of IND application for ADI-212
Adicet Bio (ACET) announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application for ADI-212 for the treatment of patients with metastatic castrati...
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies ...
Adicet Bio Transcript: Canaccord Genuity's 46th Annual Growth Conference
Significant upcoming data releases are expected for allogeneic cell therapies in LN, SLE, prostate cancer, and systemic sclerosis, with the largest data set to date in LN/SLE. The lead therapy offers a well-tolerated, off-the-shelf alternative to autologous CAR T, with pivotal studies and regulatory updates forthcoming.
Adicet Bio price target lowered to $90 from $100 at Guggenheim
Guggenheim lowered the firm’s price target on Adicet Bio (ACET) to $90 from $100 and keeps a Buy rating on the shares. The firm’s lowered target reflects the company’s updated…
Adicet Bio reports Q2 EPS ($1.99), consensus ($1.64)
“At Adicet, we continue to advance prula-cel toward our next important clinical milestone, with a Phase 1 clinical update now expected in the third quarter of 2026. The additional follow-up…
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Quarterly report: Q2 2026
Adicet Bio has published its Q2 2026 quarterly earnings report on August 5, 2026.
Adicet Bio Earnings release: Q2 2026
Adicet Bio released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Adicet Bio Slides: Investor presentation
Adicet Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals approved by stockholders. No questions were raised, and quorum was established. Final voting results will be reported in official filings.
Adicet Bio Transcript: Jefferies Global Healthcare Conference 2026
Gamma delta 1 T cell therapies are advancing in multiple autoimmune indications, with a major data update expected mid-year for prula-cel in LN and SLE. Safety and efficacy trends are promising, and a new solid tumor program (ADI-212) is set to enter the clinic soon.
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio reports Q1 EPS ($1.88), consensus ($3.08)
“Adicet is approaching a key inflection point as we prepare to report Phase 1 data for prula-cel in mid-year 2026, including data from at least 20 LN and SLE patients…
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Earnings release: Q1 2026
Adicet Bio released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Adicet Bio Quarterly report: Q1 2026
Adicet Bio has published its Q1 2026 quarterly earnings report on May 13, 2026.
Adicet Bio Slides: Investor presentation
Adicet Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Adicet Bio assumed with a Buy at Jefferies
Jefferies assumed coverage of Adicet Bio (ACET) with a Buy rating and a price target of $19, up from $8. Despite early Phase I data with its off-the-shelf allogeneic CD20…
Adicet Bio Proxy statement: Proxy filing
Adicet Bio filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Adicet Bio Proxy statement: Proxy filing
Adicet Bio filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Adicet Bio price target lowered to $27 from $50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Adicet Bio (ACET) to $27 from $50 and keeps a Buy rating on the shares following the Q4 report. The firm cites…
Adicet Bio price target lowered to $100 from $128 at Guggenheim
Guggenheim lowered the firm’s price target on Adicet Bio (ACET) to $100 from $128 and keeps a Buy rating on the shares following the company’s Q4 update. With accelerating enrollment…
Adicet Bio files $250M mixed securities shelf
17:19 EDT Adicet Bio (ACET) files $250M mixed securities shelf
Adicet Bio Annual report: Q4 2025
Adicet Bio has published its Q4 2025 annual report on March 12, 2026.